Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ju Bai

Showing results (111-120 of 119) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 119 results.
Hemasphere|November 20, 2024
The incidence and clinical significance of monoclonal and oligoclonal protein bands in multiple myeloma patients after BCMA-CAR-T cell therapy: A retrospective study based on LEGEND-2Rui Liu, Gongzhizi Gao, Hongli Chen, et al.
Frontiers of Medicine|October 2, 2019
Management of cytokine release syndrome related to CAR-T cell therapyHongli Chen, Fangxia Wang, Pengyu Zhang, et al.
Zhongguo Shi Yan Xue Ye Xue Za Zhi|May 7, 2016
[Comparison of the Effectiveness and Safety of Combined Chemotherapy with PEG-Asp for Treatment of ALL and T-NHL Patients]Yan Xu, Jin Wang, Nan Yang, et al.
Acta Haematologica|October 10, 2019
High Expression Levels of Long Noncoding RNA Small Nucleolar RNA Host Gene 18 and Semaphorin 5A Indicate Poor Prognosis in Multiple MyelomaLing-Juan Huang, Ying Shen, Ju Bai, et al.
Journal of Medicinal Chemistry|November 21, 2023
Imidazolone as an Amide Bioisostere in the Development of β-1,3-<i>N</i>-Acetylglucosaminyltransferase 2 (B3GNT2) InhibitorsJeffrey J Jackson, Aaron C Siegmund, Wen-Ju Bai, et al.
Journal of Medical Case Reports|December 10, 2022
Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case reportBai-Yan Wang, Wan-Hong Zhao, Yin-Xia Chen, et al.
Journal of Hematology & Oncology|December 22, 2018
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myelomaWan-Hong Zhao, Jie Liu, Bai-Yan Wang, et al.
Journal of Hematology & Oncology|July 6, 2022
Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)Wan-Hong Zhao, Bai-Yan Wang, Li-Juan Chen, et al.
Emerging Infectious Diseases|May 3, 2011
Japanese encephalitis, Tibet, ChinaYi-Xing Li, Ming-Hua Li, Shi-Hong Fu, et al.
Pageof 12

Showing results (111-120 of 119) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 119 results.
Hemasphere|November 20, 2024
The incidence and clinical significance of monoclonal and oligoclonal protein bands in multiple myeloma patients after BCMA-CAR-T cell therapy: A retrospective study based on LEGEND-2Rui Liu, Gongzhizi Gao, Hongli Chen, et al.
Frontiers of Medicine|October 2, 2019
Management of cytokine release syndrome related to CAR-T cell therapyHongli Chen, Fangxia Wang, Pengyu Zhang, et al.
Zhongguo Shi Yan Xue Ye Xue Za Zhi|May 7, 2016
[Comparison of the Effectiveness and Safety of Combined Chemotherapy with PEG-Asp for Treatment of ALL and T-NHL Patients]Yan Xu, Jin Wang, Nan Yang, et al.
Acta Haematologica|October 10, 2019
High Expression Levels of Long Noncoding RNA Small Nucleolar RNA Host Gene 18 and Semaphorin 5A Indicate Poor Prognosis in Multiple MyelomaLing-Juan Huang, Ying Shen, Ju Bai, et al.
Journal of Medicinal Chemistry|November 21, 2023
Imidazolone as an Amide Bioisostere in the Development of β-1,3-<i>N</i>-Acetylglucosaminyltransferase 2 (B3GNT2) InhibitorsJeffrey J Jackson, Aaron C Siegmund, Wen-Ju Bai, et al.
Journal of Medical Case Reports|December 10, 2022
Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case reportBai-Yan Wang, Wan-Hong Zhao, Yin-Xia Chen, et al.
Journal of Hematology & Oncology|December 22, 2018
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myelomaWan-Hong Zhao, Jie Liu, Bai-Yan Wang, et al.
Journal of Hematology & Oncology|July 6, 2022
Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)Wan-Hong Zhao, Bai-Yan Wang, Li-Juan Chen, et al.
Emerging Infectious Diseases|May 3, 2011
Japanese encephalitis, Tibet, ChinaYi-Xing Li, Ming-Hua Li, Shi-Hong Fu, et al.
Pageof 12